-+ 0.00%
-+ 0.00%
-+ 0.00%

EQT Unit Backs Vaderis Therapeutics' Series B Round

MT Newswires·08/11/2026 07:35:42
Listen to the news
07:35 AM EDT, 08/11/2026 (MT Newswires) -- EQT's (EQT.ST) EQT Life Sciences invested $17.5 million in Vaderis Therapeutics as part of the Swiss biopharmaceutical company's $152 million Series B funding round. The funds will support the launch of a global Phase 3 study for engasertib, a potential first treatment for hereditary hemorrhagic telangiectasia, a rare genetic vascular disease, according to a Tuesday release. The Swedish private equity group co-led the round alongside Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, Perceptive Advisors, Kalehua Capital and returning investors Medicxi and Droia.